Compare Dover Corp (DOV) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Heron Therapeutics Inc — how do they compare? Dover Corp trades at $216.11 (market cap $28.84B), while Heron Therapeutics Inc trades at $0.43 (market cap $82.52M). The key difference: Dover Corp is far larger — about 349.5× Heron Therapeutics Inc's market cap, and Dover Corp pays a 0.97% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DOV | HRTX | |
|---|---|---|
Market Cap | $28.84B | $82.52M |
Sector | Industrials | Health |
52-Week High | $233.31 | $2.04 |
52-Week Low | $161.16 | $0.39 |
Enterprise Value | $30.49B | $180.42M |
Dividend Yield | 0.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $214.27, down 0.49% on the day, with a bearish technical signal and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $2.72. Financials show solid profitability with a 13.3% net income margin and 15.06% ROE, though cash flow turned negative in 2025. Recent news highlights product launches in fueling solutions and data center technologies, indicating ongoing innovation.
The outlook is mixed: strong analyst consensus (64% buy ratings) and a $250.67 price target suggest upside, but bearish technicals and negative net cash flow pose near-term risks. Investors should weigh robust fundamentals against market volatility and execution challenges in a competitive industrial sector.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
